Cyclerion Therapeutics (CYCN) Change in Receivables (2021 - 2025)
Cyclerion Therapeutics (CYCN) posted quarterly Change in Receivables of -$425000.0 for Q3 2025, down 658.93% quarter-over-quarter from -$56000.0 in Q2 2025.
Cyclerion Therapeutics (CYCN) Change in Receivables (2021 - 2025) Analysis & Trends
Cyclerion Therapeutics' Change in Receivables history runs 5 years deep, the most recent figure standing at -$425000.0 for Q3 2025.
- In Q3 2025, Change in Receivables changed N/A year-over-year to -$425000.0; the TTM figure through Sep 2025 stood at $100000.0 (changed N/A YoY), while the FY2024 annual figure was $556000.0, up 679.17% from the prior year.
- Change in Receivables for Q3 2025 stood at -$425000.0, down from -$56000.0 in the prior quarter.
- The five-year high for Change in Receivables was $556000.0 in Q4 2024, with the low at -$425000.0 in Q3 2025.
- The 5-year median for Change in Receivables is -$56000.0 (2025), against an average of $11111.1.
- Peak annual rise in Change in Receivables reached 125.86% in 2022, while the deepest fall reached 125.86% in 2022.
- Cyclerion Therapeutics' Change in Receivables stood at -$58000.0 in 2021, then slumped by 125.86% to -$131000.0 in 2022, then advanced by 26.72% to -$96000.0 in 2023, then soared by 679.17% to $556000.0 in 2024, then slumped by 176.44% to -$425000.0 in 2025.
- Business Quant data shows CYCN's Change in Receivables at -$425000.0 in Q3 2025, -$56000.0 in Q2 2025, and $25000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Cyclerion Therapeutics | 12.71 Mn | 9.47 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -425,000.00 |
| Sep 30, 2025 | -425,000.00 |
| Jun 30, 2025 | -56,000.00 |
| Jun 30, 2025 | -56,000.00 |
| Mar 31, 2025 | 25,000.00 |
| Mar 31, 2025 | 25,000.00 |
| Dec 31, 2024 | 556,000.00 |
| Dec 31, 2024 | 556,000.00 |
| Jun 30, 2023 | -96,000.00 |
| Jun 30, 2023 | -96,000.00 |
| Dec 31, 2022 | -131,000.00 |
| Dec 31, 2022 | -131,000.00 |
| Mar 31, 2022 | 127,000.00 |
| Mar 31, 2022 | 127,000.00 |
| Dec 31, 2021 | -58,000.00 |
| Dec 31, 2021 | -58,000.00 |
| Sep 30, 2021 | 158,000.00 |
| Sep 30, 2021 | 158,000.00 |